PHASE II SAFETY AND EFFICACY STUDY OF CG0070 ONCOLYTIC VECTOR REGIMEN IN PATIENTS WITH HIGH GRADE NON-MUSCLE INVASIVE BLADDER CARCINOMA DISEASE (NMIBC) WHO HAVE FAILED BCG AND REFUSED CYSTECTOMY

Trial Profile

PHASE II SAFETY AND EFFICACY STUDY OF CG0070 ONCOLYTIC VECTOR REGIMEN IN PATIENTS WITH HIGH GRADE NON-MUSCLE INVASIVE BLADDER CARCINOMA DISEASE (NMIBC) WHO HAVE FAILED BCG AND REFUSED CYSTECTOMY

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs CG 0070 (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Acronyms exBOND
  • Sponsors Cold Genesys
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top